Etravirine (BioDeep_00000273057)
代谢物信息卡片
Etravirine (TMC125)
化学式: C20H15BrN6O (434.049064)
中文名称: 依曲韦林
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N
InChI: InChI=1S/C20H15BrN6O/c1-11-7-14(10-23)8-12(2)17(11)28-19-16(21)18(24)26-20(27-19)25-15-5-3-13(9-22)4-6-15/h3-8H,1-2H3,(H3,24,25,26,27)
描述信息
J - Antiinfectives for systemic use > J05 - Antivirals for systemic use > J05A - Direct acting antivirals > J05AG - Non-nucleoside reverse transcriptase inhibitors
C471 - Enzyme Inhibitor > C1589 - Reverse Transcriptase Inhibitor > C97453 - Non-nucleoside Reverse Transcriptase Inhibitor
D000890 - Anti-Infective Agents > D000998 - Antiviral Agents > D018894 - Reverse Transcriptase Inhibitors
D004791 - Enzyme Inhibitors > D019384 - Nucleic Acid Synthesis Inhibitors
C254 - Anti-Infective Agent > C281 - Antiviral Agent
同义名列表
2 个代谢物同义名
数据库引用编号
7 个数据库交叉引用编号
- ChEBI: CHEBI:63589
- KEGGdrug: D04112
- PubChem: 193962
- DrugBank: DB06414
- ChEMBL: CHEMBL308954
- CAS: 269055-15-4
- PMhub: MS000004799
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Satish Rojekar, Leila Fotooh Abadi, Rohan Pai, Mahendra Kumar Prajapati, Smita Kulkarni, Pradeep R Vavia. Mannose-Anchored Nano-Selenium Loaded Nanostructured Lipid Carriers of Etravirine for Delivery to HIV Reservoirs.
AAPS PharmSciTech.
2022 Aug; 23(7):230. doi:
10.1208/s12249-022-02377-8. [PMID: 35978154] - Katy Moore, Nilay Thakkar, Mindy Magee, Heather Sevinsky, Blisse Vakkalagadda, Susan Lubin, Cyril Llamoso, Peter Ackerman. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
Antimicrobial agents and chemotherapy.
2022 04; 66(4):e0225121. doi:
10.1128/aac.02251-21. [PMID: 35315687] - Satish Rojekar, Rohan Pai, Leila Fotooh Abadi, Ketan Mahajan, Mahendra Kumar Prajapati, Smita Kulkarni, Pradeep Vavia. Dual loaded nanostructured lipid carrier of nano-selenium and Etravirine as a potential anti-HIV therapy.
International journal of pharmaceutics.
2021 Sep; 607(?):120986. doi:
10.1016/j.ijpharm.2021.120986. [PMID: 34389421] - Satish Rojekar, Leila Fotooh Abadi, Rohan Pai, Ketan Mahajan, Smita Kulkarni, Pradeep R Vavia. Multi-organ targeting of HIV-1 viral reservoirs with etravirine loaded nanostructured lipid carrier: An in-vivo proof of concept.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2021 Sep; 164(?):105916. doi:
10.1016/j.ejps.2021.105916. [PMID: 34166780] - Romain Palich, Clotilde Allavena, Gilles Peytavin, Cathia Soulie, Roland Tubiana, Laurence Weiss, Ana Montoya Ferrer, Claudine Duvivier, Olivier Bouchaud, Julie Bottero, Aurore Durand, Minh-Patrick Lê, Anne-Geneviève Marcelin, Yasmine Dudoit, Lambert Assoumou, Christine Katlama. Once-daily etravirine/raltegravir (400/800 mg q24h) dual therapy maintains viral suppression over 48 weeks in HIV-infected patients switching from a twice-daily etravirine/raltegravir (200/400 mg q12h) regimen.
The Journal of antimicrobial chemotherapy.
2021 01; 76(2):477-481. doi:
10.1093/jac/dkaa423. [PMID: 33099638] - Agnieszka Matuszewska, Beata Nowak, Wojciech Niżański, Maria Eberhardt, Kinga Domrazek, Anna Nikodem, Benita Wiatrak, Krzysztof Zduniak, Kamil Olejnik, Anna Merwid-Ląd, Tomasz Tomkalski, Diana Jędrzejuk, Ewa Szeląg, Marzenna Podhorska-Okołów, Aleksandra Piotrowska, Izabela Jęśkowiak, Agata Heinrich, Maria Rutkowska, Wojciech Dziewiszek, Tomasz Sozański, Joanna Kwiatkowska, Paulina Jawień, Marek Bolanowski, Adam Szeląg. Long-Term Administration of Abacavir and Etravirine Impairs Semen Quality and Alters Redox System and Bone Metabolism in Growing Male Wistar Rats.
Oxidative medicine and cellular longevity.
2021; 2021(?):5596090. doi:
10.1155/2021/5596090. [PMID: 34373766] - Purushothaman Indu, Marimuthu Ragavan Rameshkumar, Narasingam Arunagirinathan, Naif Abdullah Al-Dhabi, Mariadhas Valan Arasu, Savarimuthu Ignacimuthu. Raltegravir, Indinavir, Tipranavir, Dolutegravir, and Etravirine against main protease and RNA-dependent RNA polymerase of SARS-CoV-2: A molecular docking and drug repurposing approach.
Journal of infection and public health.
2020 Dec; 13(12):1856-1861. doi:
10.1016/j.jiph.2020.10.015. [PMID: 33168456] - Cathia Soulie, Lambert Assoumou, Basma Abdi, Sophie Sayon, Thuy Nguyen, Marc-Antoine Valantin, Lydie Beniguel, Virginie Ferre, Chakib Alloui, Brigitte Montes, Véronique Avettand-Fenoel, Constance Delaugerre, Diane Descamps, Esteban Martinez, Jacques Reynes, Gilles Peytavin, Dominique Costagliola, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin. Characterization of viral rebounds on dual etravirine/raltegravir maintenance therapy (ANRS-163 ETRAL trial).
The Journal of antimicrobial chemotherapy.
2020 07; 75(7):1943-1949. doi:
10.1093/jac/dkaa090. [PMID: 32259255] - Beatriz Grinsztejn, Michael D Hughes, Justin Ritz, Robert Salata, Peter Mugyenyi, Evelyn Hogg, Linda Wieclaw, Robert Gross, Catherine Godfrey, Sandra W Cardoso, Aggrey Bukuru, Mumbi Makanga, Sharlaa Faesen, Vidya Mave, Beatrice Wangari Ndege, Sandy Nerette Fontain, Wadzanai Samaneka, Rode Secours, Marije van Schalkwyk, Rosie Mngqibisa, Lerato Mohapi, Javier Valencia, Patcharaphan Sugandhavesa, Esmelda Montalban, Anchalee Avihingsanon, Breno R Santos, Nagalingeswaran Kumarasamy, Cecilia Kanyama, Robert T Schooley, John W Mellors, Carole L Wallis, Ann C Collier. Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study.
The lancet. HIV.
2019 09; 6(9):e588-e600. doi:
10.1016/s2352-3018(19)30146-8. [PMID: 31371262] - Christine Katlama, Lambert Assoumou, Marc-Antoine Valantin, Cathia Soulié, Esteban Martinez, Lydie Béniguel, Olivier Bouchaud, François Raffi, Jean-Michel Molina, Soraya Fellahi, Gilles Peytavin, Anne-Geneviève Marcelin, Sami Kolta, Jacqueline Capeau, Severine Gibowski, Fanny Cardon, Jacques Reynes, Dominique Costagliola. Dual therapy combining raltegravir with etravirine maintains a high level of viral suppression over 96 weeks in long-term experienced HIV-infected individuals over 45 years on a PI-based regimen: results from the Phase II ANRS 163 ETRAL study.
The Journal of antimicrobial chemotherapy.
2019 09; 74(9):2742-2751. doi:
10.1093/jac/dkz224. [PMID: 31269208] - Minh Patrick Lê, Marc-Antoine Valantin, Lambert Assoumou, Cathia Soulie, Soizic Le Mestre, Laurence Weiss, Yazdan Yazdanpanah, Jean-Michel Molina, Olivier Bouchaud, François Raffi, Jacques Reynes, Vincent Calvez, Anne-Geneviève Marcelin, Dominique Costagliola, Christine Katlama, Gilles Peytavin. Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS-163 ETRAL Study.
Pharmacotherapy.
2019 04; 39(4):514-520. doi:
10.1002/phar.2242. [PMID: 30815916] - Ana L A Godinho, Inês L Martins, João Nunes, Catarina Charneira, Jorge Grilo, Diogo M Silva, Sofia A Pereira, Karina Soto, M Conceição Oliveira, M Matilde Marques, Cristina C Jacob, Alexandra M M Antunes. High resolution mass spectrometry-based methodologies for identification of Etravirine bioactivation to reactive metabolites: In vitro and in vivo approaches.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
2018 Jul; 119(?):70-82. doi:
10.1016/j.ejps.2018.03.026. [PMID: 29592839] - Boshi Huang, Xinhao Liu, Ye Tian, Dongwei Kang, Zhongxia Zhou, Dirk Daelemans, Erik De Clercq, Christophe Pannecouque, Peng Zhan, Xinyong Liu. First discovery of a potential carbonate prodrug of NNRTI drug candidate RDEA427 with submicromolar inhibitory activity against HIV-1 K103N/Y181C double mutant strain.
Bioorganic & medicinal chemistry letters.
2018 05; 28(8):1348-1351. doi:
10.1016/j.bmcl.2018.03.012. [PMID: 29534929] - José Moltó, Adrian Curran, Cristina Miranda, Elizabeth Challenger, José Ramón Santos, Esteban Ribera, Saye Khoo, Marta Valle, Bonaventura Clotet. Pharmacokinetics of darunavir/cobicistat and etravirine alone and co-administered in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2018 03; 73(3):732-737. doi:
10.1093/jac/dkx459. [PMID: 29237008] - Leonardo Calza, Eleonora Magistrelli, Vincenzo Colangeli, Roberto Manfredi, Marco Borderi, Nicolo' Rossi, Matteo Conti, Rita Mancini, Pierluigi Viale. Dual Raltegravir-Etravirine Combination as Maintenance Regimen in Virologically Suppressed HIV-1-Infected Patients.
AIDS research and human retroviruses.
2017 07; 33(7):632-638. doi:
10.1089/aid.2016.0291. [PMID: 28088884] - Lei Wei, Hui-Ling Wang, Li Huang, Chin-Ho Chen, Susan L Morris-Natschke, Kuo-Hsiung Lee, Lan Xie. Drug-like property-driven optimization of 4-substituted 1,5-diarylanilines as potent HIV-1 non-nucleoside reverse transcriptase inhibitors against rilpivirine-resistant mutant virus.
Bioorganic & medicinal chemistry letters.
2017 06; 27(12):2788-2792. doi:
10.1016/j.bmcl.2017.04.068. [PMID: 28465101] - Bruce Green, Herta Crauwels, Thomas N Kakuda, Simon Vanveggel, Anne Brochot. Evaluation of Concomitant Antiretrovirals and CYP2C9/CYP2C19 Polymorphisms on the Pharmacokinetics of Etravirine.
Clinical pharmacokinetics.
2017 05; 56(5):525-536. doi:
10.1007/s40262-016-0454-8. [PMID: 27665573] - Teresa L Parsons, Mark A Marzinke. Development and validation of a liquid chromatographic-tandem mass spectrometric method for the multiplexed quantification of etravirine, maraviroc, raltegravir, and rilpivirine in human plasma and tissue.
Journal of pharmaceutical and biomedical analysis.
2016 Nov; 131(?):333-344. doi:
10.1016/j.jpba.2016.08.016. [PMID: 27632783] - Moti Ramgopal, Olayemi Osiyemi, Carmen Zorrilla, Herta M Crauwels, Robert Ryan, Kimberley Brown, Vera Hillewaert, Bryan Baugh. Pharmacokinetics of Total and Unbound Etravirine in HIV-1-Infected Pregnant Women.
Journal of acquired immune deficiency syndromes (1999).
2016 11; 73(3):268-274. doi:
10.1097/qai.0000000000001068. [PMID: 27159225] - Zhaleh Ghaemi, Domenico Alberga, Paolo Carloni, Alessandro Laio, Gianluca Lattanzi. Permeability Coefficients of Lipophilic Compounds Estimated by Computer Simulations.
Journal of chemical theory and computation.
2016 Aug; 12(8):4093-9. doi:
10.1021/acs.jctc.5b01126. [PMID: 27392273] - Anna K Blakney, Yonghou Jiang, Dale Whittington, Kim A Woodrow. Simultaneous measurement of etravirine, maraviroc and raltegravir in pigtail macaque plasma, vaginal secretions and vaginal tissue using a LC-MS/MS assay.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2016 Jul; 1025(?):110-8. doi:
10.1016/j.jchromb.2016.04.048. [PMID: 27236000] - Alexander N Geisman, Vladimir T Valuev-Elliston, Alexander A Ozerov, Anastasia L Khandazhinskaya, Alexander O Chizhov, Sergey N Kochetkov, Christophe Pannecouque, Lieve Naesens, Katherine L Seley-Radtke, Mikhail S Novikov. 1,6-Bis[(benzyloxy)methyl]uracil derivatives-Novel antivirals with activity against HIV-1 and influenza H1N1 virus.
Bioorganic & medicinal chemistry.
2016 06; 24(11):2476-85. doi:
10.1016/j.bmc.2016.04.010. [PMID: 27112451] - Leïla Belkhir, Morgane De Laveleye, Bernard Vandercam, Francis Zech, Kevin-Alexandre Delongie, Arnaud Capron, Jean Yombi, Anne Vincent, Laure Elens, Vincent Haufroid. Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LC-MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drug-drug interaction.
Clinical biochemistry.
2016 May; 49(7-8):580-6. doi:
10.1016/j.clinbiochem.2015.12.011. [PMID: 26742721] - Leïla Belkhir, Laure Elens, Francis Zech, Nadtha Panin, Anne Vincent, Jean Cyr Yombi, Bernard Vandercam, Vincent Haufroid. Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism.
PloS one.
2016; 11(10):e0165631. doi:
10.1371/journal.pone.0165631. [PMID: 27788239] - Carlos Brites, Isabella Nóbrega, Eduardo Martins Netto. Use of new antiretroviral drugs and classes in Bahia, Brazil: a real life experience on salvage therapy of AIDS patients.
The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases.
2015 Sep; 19(5):529-32. doi:
10.1016/j.bjid.2015.03.005. [PMID: 25997781] - Laura Ciaffi, Matthias Cavassini, Daniel Genne, Cecile Delhumeau, Rachel Spycher Elbes, Andrew Hill, Gilles Wandeler, Jan Fehr, Marcel Stoeckle, Patrick Schmid, Bernard Hirschel, Fabrizio Montecucco, Alexandra Calmy. Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study.
European journal of clinical investigation.
2015 Jul; 45(7):720-30. doi:
10.1111/eci.12464. [PMID: 25989829] - P J Ruane, C Brinson, M Ramgopal, R Ryan, B Coate, M Cho, T N Kakuda, D Anderson. The Intelence aNd pRezista Once A Day Study (INROADS): a multicentre, single-arm, open-label study of etravirine and darunavir/ritonavir as dual therapy in HIV-1-infected early treatment-experienced subjects.
HIV medicine.
2015 May; 16(5):288-96. doi:
10.1111/hiv.12211. [PMID: 25585528] - S Gallien, I Charreau, M L Nere, N Mahjoub, F Simon, N de Castro, J P Aboulker, J M Molina, C Delaugerre. Archived HIV-1 DNA resistance mutations to rilpivirine and etravirine in successfully treated HIV-1-infected individuals pre-exposed to efavirenz or nevirapine.
The Journal of antimicrobial chemotherapy.
2015 Feb; 70(2):562-5. doi:
10.1093/jac/dku395. [PMID: 25344807] - Michael Sension, Henri Deckx. Lipid metabolism and lipodystrophy in HIV-1-infected patients: the role played by nonnucleoside reverse transcriptase inhibitors.
AIDS reviews.
2015 Jan; 17(1):21-36. doi:
NULL. [PMID: 25472015] - José L Casado, Sara Bañón, Miguel A Rodriguez, Ana Moreno, Santiago Moreno. Efficacy and pharmacokinetics of the combination of etravirine plus raltegravir as novel dual antiretroviral maintenance regimen in HIV-infected patients.
Antiviral research.
2015 Jan; 113(?):103-6. doi:
10.1016/j.antiviral.2014.11.006. [PMID: 25460844] - David Burger, Stefanie Krens, Karen Robijns, Rob Aarnoutse, Roger Brüggemann, Daan Touw. Poor performance of laboratories assaying newly developed antiretroviral agents: results for darunavir, etravirine, and raltegravir from the international quality control program for therapeutic drug monitoring of antiretroviral drugs in human plasma/serum.
Therapeutic drug monitoring.
2014 Dec; 36(6):824-7. doi:
10.1097/ftd.0000000000000089. [PMID: 24819970] - G Tudor-Williams, P Cahn, K Chokephaibulkit, J Fourie, C Karatzios, S Dincq, M Opsomer, T N Kakuda, S Nijs, L Tambuyzer, F L Tomaka. Etravirine in treatment-experienced, HIV-1-infected children and adolescents: 48-week safety, efficacy and resistance analysis of the phase II PIANO study.
HIV medicine.
2014 Oct; 15(9):513-24. doi:
10.1111/hiv.12141. [PMID: 24589294] - A Calcagno, L Marinaro, S Nozza, C Aldieri, A Carbone, V Ghisetti, A Trentalange, A D'Avolio, A Castagna, G Di Perri, S Bonora. Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients.
Antiviral research.
2014 Aug; 108(?):44-7. doi:
10.1016/j.antiviral.2014.05.009. [PMID: 24861522] - R Gagliardini, M Fabbiani, S Fortuna, E Visconti, P Navarra, R Cauda, M Colafigli, A De Luca, E M Trecarichi, S Di Giambenedetto. Pharmacokinetics of etravirine in HIV-infected patients concomitantly treated with rifampin for tuberculosis.
Infection.
2014 Aug; 42(4):775-8. doi:
10.1007/s15010-014-0599-z. [PMID: 24531907] - Thomas N Kakuda, Lorant Leopold, Steven Nijs, Ann Vandevoorde, Herta M Crauwels, Kirk M Bertelsen, Marita Stevens, James Witek, Yvon van Delft, Frank Tomaka, Richard M W Hoetelmans. Pharmacokinetic interaction between etravirine or rilpivirine and telaprevir in healthy volunteers: A randomized, two-way crossover trial.
Journal of clinical pharmacology.
2014 May; 54(5):563-73. doi:
10.1002/jcph.245. [PMID: 25975423] - Anna Maria Geretti, Tim Conibear, Andrew Hill, Jeffrey A Johnson, Lotke Tambuyzer, Kim Thys, Johan Vingerhoets, Yvon Van Delft. Sensitive testing of plasma HIV-1 RNA and Sanger sequencing of cellular HIV-1 DNA for the detection of drug resistance prior to starting first-line antiretroviral therapy with etravirine or efavirenz.
The Journal of antimicrobial chemotherapy.
2014 Apr; 69(4):1090-7. doi:
10.1093/jac/dkt474. [PMID: 24284781] - Polyana Monteiro, Iñaki Perez, Montserrat Laguno, Maria Martínez-Rebollar, Ana González-Cordon, Montserrat Lonca, Josep Mallolas, Jose L Blanco, Jose M Gatell, Esteban Martínez. Dual therapy with etravirine plus raltegravir for virologically suppressed HIV-infected patients: a pilot study.
The Journal of antimicrobial chemotherapy.
2014 Mar; 69(3):742-8. doi:
10.1093/jac/dkt406. [PMID: 24128667] - Patricia Echeverría, Anna Bonjoch, Jordi Puig, José Moltó, Roger Paredes, Guillem Sirera, Arelly Ornelas, Nuria Pérez-Álvarez, Bonaventura Clotet, Eugènia Negredo. Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.
PloS one.
2014; 9(2):e84676. doi:
10.1371/journal.pone.0084676. [PMID: 24503952] - Luis F López-Cortés, Pompeyo Viciana, José A Girón-González, Alberto Romero-Palacios, Manuel Márquez-Solero, Maria A Martinez-Perez, Miguel A López-Ruz, Javier de la Torre-Lima, Francisco Téllez-Pérez, Marcial Delgado-Fernández, Milagros Garcia-Lázaro, Fernando Lozano, Mohamed O Mohamed-Balghata. Clinical and virological efficacy of etravirine plus two active Nucleos(t)ide analogs in an heterogeneous HIV-infected population.
PloS one.
2014; 9(5):e97262. doi:
10.1371/journal.pone.0097262. [PMID: 24836963] - Zoubir Djerada, Catherine Feliu, Claire Tournois, Damien Vautier, Laurent Binet, Arnaud Robinet, Hélène Marty, Claire Gozalo, Denis Lamiable, Hervé Millart. Validation of a fast method for quantitative analysis of elvitegravir, raltegravir, maraviroc, etravirine, tenofovir, boceprevir and 10 other antiretroviral agents in human plasma samples with a new UPLC-MS/MS technology.
Journal of pharmaceutical and biomedical analysis.
2013 Dec; 86(?):100-11. doi:
10.1016/j.jpba.2013.08.002. [PMID: 23995753] - Lindsay B Avery, Melissa A Zarr, Rahul P Bakshi, Robert F Siliciano, Craig W Hendrix. Increasing extracellular protein concentration reduces intracellular antiretroviral drug concentration and antiviral effect.
AIDS research and human retroviruses.
2013 Nov; 29(11):1434-42. doi:
10.1089/aid.2013.0031. [PMID: 23601085] - Eugène Messou, Marie-Laure Chaix, Delphine Gabillard, Vincent Yapo, Thomas-d'Aquin Toni, Albert Minga, Martial Guillaume Kouakou, Eric Ouattara, Christine Rouzioux, Christine Danel, Serge P Eholie, Xavier Anglaret. Increasing rate of TAMs and etravirine resistance in HIV-1-infected adults between 12 and 24 months of treatment: the VOLTART cohort study in Côte d'Ivoire, West Africa.
Journal of acquired immune deficiency syndromes (1999).
2013 Oct; 64(2):211-9. doi:
10.1097/qai.0b013e3182a009e4. [PMID: 23797690] - Thomas N Kakuda, Cindy Berckmans, Goedele De Smedt, Ruud Leemans, Lorant Leopold, Monika Peeters, Steven Nijs, Veerle Vyncke, Rodica van Solingen-Ristea, Richard M W Hoetelmans. Single-dose pharmacokinetics of pediatric and adult formulations of etravirine and swallowability of the 200-mg tablet: results from three Phase 1 studies.
International journal of clinical pharmacology and therapeutics.
2013 Sep; 51(9):725-37. doi:
10.5414/cp201770. [PMID: 23924679] - T N Kakuda, R DeMasi, Y van Delft, P Mohammed. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
HIV medicine.
2013 Aug; 14(7):421-9. doi:
10.1111/hiv.12019. [PMID: 23441978] - Anh Nguyen, Steven Rossi, David Croteau, Brookie M Best, David Clifford, Ann C Collier, Benjamin Gelman, Christina Marra, Justin McArthur, J Allen McCutchan, Susan Morgello, David Simpson, Ronald J Ellis, Igor Grant, Edmund Capparelli, Scott Letendre. Etravirine in CSF is highly protein bound.
The Journal of antimicrobial chemotherapy.
2013 May; 68(5):1161-8. doi:
10.1093/jac/dks517. [PMID: 23335197] - Giovanni Di Perri, Bruce Green, Glynn Morrish, Andrew Hill, Gerd Faetkenheuer, Markus Bickel, Yvon van Delft, Michael Kurowski, Thomas Kakuda. Pharmacokinetics and pharmacodynamics of etravirine 400 mg once daily in treatment-naïve patients.
HIV clinical trials.
2013 May; 14(3):92-8. doi:
10.1310/hct1403-92. [PMID: 23835511] - J John, M John, L Wu, C Hsiao, C V Abobo, D Liang. Effects of etravirine on the pharmacokinetics and pharmacodynamics of warfarin in rats.
British journal of pharmacology.
2013 Apr; 168(8):1851-8. doi:
10.1111/bph.12082. [PMID: 23215758] - Eva Agneskog, Piotr Nowak, Clas F R Källander, Anders Sönnerborg. Evaluation of etravirine resistance in clinical samples by a simple phenotypic test.
Journal of medical virology.
2013 Apr; 85(4):703-8. doi:
10.1002/jmv.23507. [PMID: 23364785] - Thomas N Kakuda, Rodica Van Solingen-Ristea, Fatima Aharchi, Goedele De Smedt, James Witek, Steven Nijs, Veerle Vyncke, Richard M W Hoetelmans. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Journal of clinical pharmacology.
2013 Jan; 53(1):41-50. doi:
10.1177/0091270011433329. [PMID: 23400742] - Eric Dailly, Clotilde Allavena, Regis Bouquié, Guillaume Deslandes, François Raffi, Pascale Jolliet. Effect of efavirenz, nevirapine, etravirine, and raltegravir administration on the pharmacokinetics of ritonavir-boosted darunavir in a population of HIV-infected patients.
AIDS research and human retroviruses.
2013 Jan; 29(1):42-6. doi:
10.1089/aid.2012.0188. [PMID: 23148588] - J M Tiraboschi, J Niubo, E Ferrer, G Barrera-Castillo, N Rozas, M Maso-Serra, D Podzamczer. Etravirine concentrations in seminal plasma in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2013 Jan; 68(1):184-7. doi:
10.1093/jac/dks360. [PMID: 22954493] - Susan L Ford, Elizabeth Gould, Shuguang Chen, Yu Lou, Etienne Dumont, William Spreen, Stephen Piscitelli. Effects of etravirine on the pharmacokinetics of the integrase inhibitor S/GSK1265744.
Antimicrobial agents and chemotherapy.
2013 Jan; 57(1):277-80. doi:
10.1128/aac.01685-12. [PMID: 23114768] - Rubin Lubomirov, Mona Arab-Alameddine, Margalida Rotger, Aurélie Fayet-Mello, Raquel Martinez, Monia Guidi, Julia di Iulio, Matthias Cavassini, Huldrych F Günthard, Hansjakob Furrer, Catia Marzolini, Enos Bernasconi, Alexandra Calmy, Thierry Buclin, Laurent A Decosterd, Chantal Csajka, Amalio Telenti. Pharmacogenetics-based population pharmacokinetic analysis of etravirine in HIV-1 infected individuals.
Pharmacogenetics and genomics.
2013 Jan; 23(1):9-18. doi:
10.1097/fpc.0b013e32835ade82. [PMID: 23111422] - Kyle P Hammond, Pamela Wolfe, James R Burton, Julie A Predhomme, Christine M Ellis, Michelle L Ray, Lane R Bushman, Jennifer J Kiser. Pharmacokinetic interaction between boceprevir and etravirine in HIV/HCV seronegative volunteers.
Journal of acquired immune deficiency syndromes (1999).
2013 Jan; 62(1):67-73. doi:
10.1097/qai.0b013e318275da93. [PMID: 23075915] - José L Casado, Ignacio de Los Santos, María Del Palacio, Lucio García-Fraile, María J Pérez-Elías, Jesús Sanz, Santiago Moreno. Lipid-lowering effect and efficacy after switching to etravirine in HIV-infected patients with intolerance to suppressive HAART.
HIV clinical trials.
2013 Jan; 14(1):1-9. doi:
10.1310/hct1401-1. [PMID: 23372109] - Edward P Acosta, Kay L Limoli, Lan Trinh, Neil T Parkin, Jennifer R King, Jodi M Weidler, Ighovwerha Ofotokun, Christos J Petropoulos. Novel method to assess antiretroviral target trough concentrations using in vitro susceptibility data.
Antimicrobial agents and chemotherapy.
2012 Nov; 56(11):5938-45. doi:
10.1128/aac.00691-12. [PMID: 22964257] - Minh Patrick Lê, Caroline Solas, Rodolphe Garraffo, Marie-Claude Gagnieu, Patrice Muret, Patrick Yeni, Catherine Dhiver, Christine Katlama, Isabelle Poizot-Martin, Jacques Durant, Gilles Peytavin. Pharmacokinetic interaction between maraviroc and etravirine in HIV-infected patients receiving regimens containing both drugs and no ritonavir-boosted protease inhibitor.
The Journal of antimicrobial chemotherapy.
2012 Nov; 67(11):2779-81. doi:
10.1093/jac/dks260. [PMID: 22773742] - Kevin C Brown, Kristine B Patterson, Steven H Jennings, Stephanie A Malone, Nicholas J Shaheen, Heather M Asher Prince, Melissa Spacek, Myron S Cohen, Angela D M Kashuba. Single- and multiple-dose pharmacokinetics of darunavir plus ritonavir and etravirine in semen and rectal tissue of HIV-negative men.
Journal of acquired immune deficiency syndromes (1999).
2012 Oct; 61(2):138-44. doi:
10.1097/qai.0b013e31825cb645. [PMID: 22614898] - José Moltó, Marta Valle, Cristina Miranda, Samandhy Cedeño, Eugenia Negredo, Bonaventura Clotet. Herb-drug interaction between Echinacea purpurea and etravirine in HIV-infected patients.
Antimicrobial agents and chemotherapy.
2012 Oct; 56(10):5328-31. doi:
10.1128/aac.01205-12. [PMID: 22869560] - Jessica H Brehm, Dianna L Koontz, Carole L Wallis, Kathleen A Shutt, Ian Sanne, Robin Wood, James A McIntyre, Wendy S Stevens, Nicolas Sluis-Cremer, John W Mellors. Frequent emergence of N348I in HIV-1 subtype C reverse transcriptase with failure of initial therapy reduces susceptibility to reverse-transcriptase inhibitors.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
2012 Sep; 55(5):737-45. doi:
10.1093/cid/cis501. [PMID: 22618567] - L Schneider, N Ktorza, S Fourati, L Assoumou, E Courbon, F Caby, C Blanc, M Tindel, R Agher, A G Marcelin, V Calvez, G Peytavin, C Katlama. Switch from etravirine twice daily to once daily in non-nucleoside reverse transcriptase inhibitor (NNRTI)-resistant HIV-infected patients with suppressed viremia: the Monetra study.
HIV clinical trials.
2012 Sep; 13(5):284-8. doi:
10.1310/hct1305-284. [PMID: 23134629] - David M Asmuth, Zhong-Min Ma, Surinder Mann, Thomas H Knight, Tammy Yotter, Anthony Albanese, Gregory P Melcher, Paolo Troia-Cancio, Timothy Hayes, Chris J Miller, Richard B Pollard. Gastrointestinal-associated lymphoid tissue immune reconstitution in a randomized clinical trial of raltegravir versus non-nucleoside reverse transcriptase inhibitor-based regimens.
AIDS (London, England).
2012 Aug; 26(13):1625-34. doi:
10.1097/qad.0b013e3283546595. [PMID: 22820612] - Jing Fang, Pravin R Jadhav. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Journal of pharmacokinetics and pharmacodynamics.
2012 Aug; 39(4):357-68. doi:
10.1007/s10928-012-9255-3. [PMID: 22736302] - P-M Girard, T B Campbell, B Grinsztejn, J Hartikainen, A Rachline, S Nijs, J Witek. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.
HIV medicine.
2012 Aug; 13(7):427-35. doi:
10.1111/j.1468-1293.2012.00994.x. [PMID: 22413938] - C Clavel, G Peytavin, R Tubiana, C Soulié, E Courbon, C Crenn-Hebert, H Ichou, C Blanc, L Schneider, C Katlama, A-G Marcelin, L Mandelbrot. Etravirine concentrations in the cervicovaginal compartment in HIV-1-infected women receiving etravirine-containing antiretroviral therapy: DIVA 02 study.
Antimicrobial agents and chemotherapy.
2012 Jul; 56(7):4018-20. doi:
10.1128/aac.06474-11. [PMID: 22526321] - M C Serrano Vicente, H Navarro Aznárez, P Carrera Lasfuentes, M R Abad Sazatornil, O Horna Oreja, M J Rabanaque Hernández. [Safety and effectiveness of salvage therapy in HIV patients].
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria.
2012 Jul; 36(4):187-93. doi:
10.1016/j.farma.2011.03.004. [PMID: 22099741] - J M Tiraboschi, J Niubo, A Vila, S Perez-Pujol, D Podzamczer. Etravirine concentrations in CSF in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2012 Jun; 67(6):1446-8. doi:
10.1093/jac/dks048. [PMID: 22357802] - Alicia Gutiérrez-Valencia, Reyes Martin-Peña, Almudena Torres-Cornejo, Rosa Ruiz-Valderas, Juan R Castillo-Ferrando, Luis F López-Cortés. Intracellular and plasma pharmacokinetics of 400 mg of etravirine once daily versus 200 mg of etravirine twice daily in HIV-infected patients.
The Journal of antimicrobial chemotherapy.
2012 Mar; 67(3):681-4. doi:
10.1093/jac/dkr534. [PMID: 22190606] - G Fätkenheuer, C Duvivier, A Rieger, J Durant, D Rey, W Schmidt, A Hill, Y van Delft, S Marks. Lipid profiles for etravirine versus efavirenz in treatment-naive patients in the randomized, double-blind SENSE trial.
The Journal of antimicrobial chemotherapy.
2012 Mar; 67(3):685-90. doi:
10.1093/jac/dkr533. [PMID: 22210755] - Christoph Königs, Cornelia Feiterna-Sperling, Susanna Esposito, Claudio Viscoli, Raffaella Rosso, Thomas N Kakuda, Ruud Leemans, Monika Peeters, Rebecca Mack, Ingeborg Peeters, Rekha Sinha, Katia Boven, Carlo Giaquinto. Pharmacokinetics and short-term safety and tolerability of etravirine in treatment-experienced HIV-1-infected children and adolescents.
AIDS (London, England).
2012 Feb; 26(4):447-55. doi:
10.1097/qad.0b013e32834f30b1. [PMID: 22156961] - Uriel Sandkovsky, Susan Swindells, Ryan Moore, Edward P Acosta, Courtney V Fletcher. Acceptable plasma concentrations of raltegravir and etravirine when administered by gastrostomy tube in a patient with advanced multidrug-resistant human immunodeficiency virus infection.
Pharmacotherapy.
2012 Feb; 32(2):142-7. doi:
10.1002/phar.1015. [PMID: 22392423] - Julie H Levison, Catherine Orrell, Sébastien Gallien, Daniel R Kuritzkes, Naishin Fu, Elena Losina, Kenneth A Freedberg, Robin Wood. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.
PloS one.
2012; 7(3):e32144. doi:
10.1371/journal.pone.0032144. [PMID: 22427821] - Johan Vingerhoets, Steven Nijs, Lotke Tambuyzer, Annemie Hoogstoel, David Anderson, Gaston Picchio. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
Antiviral therapy.
2012; 17(8):1571-9. doi:
10.3851/imp2275. [PMID: 22869341] - Ruxandra Calin, Luc Paris, Anne Simon, Gilles Peytavin, Marc Wirden, Luminita Schneider, Marc-Antoine Valantin, Roland Tubiana, Rachid Agher, Christine Katlama. Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Antiviral therapy.
2012; 17(8):1601-4. doi:
10.3851/imp2344. [PMID: 22941896] - Antonella Esposito, Marco Floridia, Gabriella d'Ettorre, Daniele Pastori, Alessandra Fantauzzi, Paola Massetti, Giancarlo Ceccarelli, Camilla Ajassa, Vincenzo Vullo, Ivano Mezzaroma. Rate and determinants of treatment response to different antiretroviral combination strategies in subjects presenting at HIV-1 diagnosis with advanced disease.
BMC infectious diseases.
2011 Dec; 11(?):341. doi:
10.1186/1471-2334-11-341. [PMID: 22166160] - Aurélie Fayet Mello, Thierry Buclin, Claudia Franc, Sara Colombo, Sandra Cruchon, Nicole Guignard, Jérôme Biollaz, Amalio Telenti, Laurent A Decosterd, Matthias Cavassini. Cell disposition of raltegravir and newer antiretrovirals in HIV-infected patients: high inter-individual variability in raltegravir cellular penetration.
The Journal of antimicrobial chemotherapy.
2011 Jul; 66(7):1573-81. doi:
10.1093/jac/dkr151. [PMID: 21508009] - Ivy Song, Julie Borland, Sherene Min, Yu Lou, Shuguang Chen, Parul Patel, Toshihiro Wajima, Stephen C Piscitelli. Effects of etravirine alone and with ritonavir-boosted protease inhibitors on the pharmacokinetics of dolutegravir.
Antimicrobial agents and chemotherapy.
2011 Jul; 55(7):3517-21. doi:
10.1128/aac.00073-11. [PMID: 21555764] - Hanady Daas, Riad Khatib, Haitham Nasser, Farah Kamran, Martha Higgins, Louis Saravolatz. Human immunodeficiency virus infection and autoimmune hepatitis during highly active anti-retroviral treatment: a case report and review of the literature.
Journal of medical case reports.
2011 Jun; 5(?):233. doi:
10.1186/1752-1947-5-233. [PMID: 21702972] - Anoumou Y Dagnra, Nicole Vidal, Akovi Mensah, Akouda Patassi, Komi Aho, Mounerou Salou, Marjorie Monleau, Mireille Prince-David, Assétina Singo, Palokinam Pitche, Eric Delaporte, Martine Peeters. High prevalence of HIV-1 drug resistance among patients on first-line antiretroviral treatment in Lomé, Togo.
Journal of the International AIDS Society.
2011 Jun; 14(?):30. doi:
10.1186/1758-2652-14-30. [PMID: 21663632] - Chiara Tommasi, Rita Bellagamba, Massimo Tempestilli, Antonio D'Avolio, Anna L Gallo, Jelena Ivanovic, Emanuele Nicastri, Leopoldo P Pucillo, Pasquale Narciso. Marked increase in etravirine and saquinavir plasma concentrations during atovaquone/proguanil prophylaxis.
Malaria journal.
2011 May; 10(?):141. doi:
10.1186/1475-2875-10-141. [PMID: 21600016] - Rob Ter Heine, Jan W Mulder, Eric Cm van Gorp, Jiri Fp Wagenaar, Jos H Beijnen, Alwin Dr Huitema. Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Bioanalysis.
2011 May; 3(10):1093-7. doi:
10.4155/bio.11.72. [PMID: 21585304] - Thomas N Kakuda, Samantha Abel, John Davis, Julia Hamlin, Monika Schöller-Gyüre, Rebecca Mack, Noella Ndongo, Wendy Petit, Caroline Ridgway, Vanitha Sekar, Sarah Tweedy, Richard M W Hoetelmans. Pharmacokinetic interactions of maraviroc with darunavir-ritonavir, etravirine, and etravirine-darunavir-ritonavir in healthy volunteers: results of two drug interaction trials.
Antimicrobial agents and chemotherapy.
2011 May; 55(5):2290-6. doi:
10.1128/aac.01046-10. [PMID: 21383098] - Kristine Patterson, Steven Jennings, Ron Falcon, Joseph Mrus, Angela Kashuba. Darunavir, ritonavir, and etravirine pharmacokinetics in the cervicovaginal fluid and blood plasma of HIV-infected women.
Antimicrobial agents and chemotherapy.
2011 Mar; 55(3):1120-2. doi:
10.1128/aac.00889-10. [PMID: 21173188] - Luke C Swenson, Graham Pollock, Brian Wynhoven, Theresa Mo, Winnie Dong, Robert S Hogg, Julio S G Montaner, P Richard Harrigan. 'Dynamic range' of inferred phenotypic HIV drug resistance values in clinical practice.
PloS one.
2011 Feb; 6(2):e17402. doi:
10.1371/journal.pone.0017402. [PMID: 21390218] - Theodoros Kelesidis, Otto O Yang, Judith S Currier, Kaveh Navab, Alan M Fogelman, Mohamad Navab. HIV-1 infected patients with suppressed plasma viremia on treatment have pro-inflammatory HDL.
Lipids in health and disease.
2011 Feb; 10(?):35. doi:
10.1186/1476-511x-10-35. [PMID: 21345230] - Asgeir Johannessen, Carolina Garrido, Natalia Zahonero, Ezra Naman, Carmen de Mendoza. HIV-1 drug resistance testing from dried blood spots collected in rural Tanzania using the ViroSeq HIV-1 Genotyping System.
The Journal of antimicrobial chemotherapy.
2011 Feb; 66(2):260-4. doi:
10.1093/jac/dkq433. [PMID: 21115444] - Arkaitz Imaz, Josep M Llibre, Marta Mora, Gracia Mateo, Angela Camacho, José R Blanco, Adrian Curran, José R Santos, Estrella Caballero, Isabel Bravo, Francisco Gayá, Pere Domingo, Antonio Rivero, Vicenç Falcó, Bonaventura Clotet, Esteban Ribera. Efficacy and safety of nucleoside reverse transcriptase inhibitor-sparing salvage therapy for multidrug-resistant HIV-1 infection based on new-class and new-generation antiretrovirals.
The Journal of antimicrobial chemotherapy.
2011 Feb; 66(2):358-62. doi:
10.1093/jac/dkq432. [PMID: 21172789] - Alain Nguyen, Alexandra Calmy, Cécile Delhumeau, Isabelle K Mercier, Matthias Cavassini, Aurélie Fayet-Mello, Luigia Elzi, Daniel Genné, Andri Rauch, Enos Bernasconi, Bernard Hirschel. A randomized crossover study to compare efavirenz and etravirine treatment.
AIDS (London, England).
2011 Jan; 25(1):57-63. doi:
10.1097/qad.0b013e32833f9f63. [PMID: 21076278] - Thomas N Kakuda, Monika Schöller-Gyüre, Richard M W Hoetelmans. Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.
Clinical pharmacokinetics.
2011 Jan; 50(1):25-39. doi:
10.2165/11534740-000000000-00000. [PMID: 21142266] - Laura J Else, Stephen Taylor, David J Back, Saye H Khoo. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract.
Antiviral therapy.
2011; 16(8):1149-67. doi:
10.3851/imp1919. [PMID: 22155899] - Andrew M Hill, Michelle Cho, Joseph M Mrus. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.
AIDS reviews.
2011 Jan; 13(1):41-8. doi:
NULL. [PMID: 21412388] - Laura J Else, Stephen Taylor, David J Back, Saye H Khoo. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the fetal compartment (placenta and amniotic fluid).
Antiviral therapy.
2011; 16(8):1139-47. doi:
10.3851/imp1918. [PMID: 22155898] - Robert Kalyesubula, Mark A Perazella. Nephrotoxicity of HAART.
AIDS research and treatment.
2011; 2011(?):562790. doi:
10.1155/2011/562790. [PMID: 21860787] - Takeshi Nishijima, Hirokazu Komatsu, Hiroyuki Gatanaga, Takahiro Aoki, Koji Watanabe, Ei Kinai, Haruhito Honda, Junko Tanuma, Hirohisa Yazaki, Kunihisa Tsukada, Miwako Honda, Katsuji Teruya, Yoshimi Kikuchi, Shinichi Oka. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.
PloS one.
2011; 6(7):e22661. doi:
10.1371/journal.pone.0022661. [PMID: 21799928] - Marco Siccardi, Antonio D'Avolio, Silvia Nozza, Marco Simiele, Lorena Baietto, Francesca Romana Stefani, Darren Moss, Wai-San Kwan, Antonella Castagna, Adriano Lazzarin, Andrea Calcagno, Stefano Bonora, David Back, Giovanni Di Perri, Andrew Owen. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism.
Pharmacogenetics and genomics.
2010 Dec; 20(12):759-65. doi:
10.1097/fpc.0b013e3283402efb. [PMID: 21217360] - Cyril V Abobo, Lei Wu, Jyothy John, Mathew K Joseph, Theodore R Bates, Dong Liang. LC-MS/MS determination of etravirine in rat plasma and its application in pharmacokinetic studies.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
2010 Nov; 878(30):3181-6. doi:
10.1016/j.jchromb.2010.09.016. [PMID: 20965798] - T Puthanakit, G Jourdain, S Hongsiriwon, P Suntarattiwong, K Chokephaibulkit, V Sirisanthana, P Kosalaraksa, W Petdachai, R Hansudewechakul, U Siangphoe, T Suwanlerk, J Ananworanich. HIV-1 drug resistance mutations in children after failure of first-line nonnucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
HIV medicine.
2010 Oct; 11(9):565-72. doi:
10.1111/j.1468-1293.2010.00828.x. [PMID: 20345882] - D S Fullerton, Mary Jane Watson, David Anderson, James Witek, Silas C Martin, Joseph M Mrus. Pharmacoeconomics of etravirine.
Expert review of pharmacoeconomics & outcomes research.
2010 Oct; 10(5):485-95. doi:
10.1586/erp.10.55. [PMID: 20950062] - Babafemi Taiwo, Robert L Murphy, Christine Katlama. Novel antiretroviral combinations in treatment-experienced patients with HIV infection: rationale and results.
Drugs.
2010 Sep; 70(13):1629-42. doi:
10.2165/11538020-000000000-00000. [PMID: 20731472]